China Pharma (CPHI) Competitors

China Pharma (NYSE:CPHI) and Equillium (NASDAQ:EQ) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, media sentiment, profitability, valuation and dividends.

Which has preferable earnings & valuation, CPHI or EQ?

China Pharma has higher earnings, but lower revenue than Equillium.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
China Pharma	$4.30M	1.09	-$3.08M	N/A	N/A
Equillium	$41.10M	0.99	-$8.07M	-$0.39	-2.92

Which has more volatility & risk, CPHI or EQ?

China Pharma has a beta of 0.87, suggesting that its share price is 13% less volatile than the S&P 500. Comparatively, Equillium has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500.

Is CPHI or EQ more profitable?

Equillium has a net margin of -19.62% compared to China Pharma's net margin of -85.56%. China Pharma's return on equity of -63.93% beat Equillium's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
China Pharma	-85.56%	-63.93%	-31.42%
Equillium	-19.62%	-114.69%	-78.89%

Do insiders and institutionals hold more shares of CPHI or EQ?

27.1% of Equillium shares are owned by institutional investors. 17.3% of China Pharma shares are owned by company insiders. Comparatively, 31.6% of Equillium shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Does the media favor CPHI or EQ?

In the previous week, Equillium had 7 more articles in the media than China Pharma. MarketBeat recorded 8 mentions for Equillium and 1 mentions for China Pharma. China Pharma's average media sentiment score of 0.50 beat Equillium's score of 0.26 indicating that China Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
China Pharma	Positive
Equillium	Neutral

Do analysts prefer CPHI or EQ?

Equillium has a consensus target price of $3.00, suggesting a potential upside of 163.16%. Given Equillium's stronger consensus rating and higher possible upside, analysts clearly believe Equillium is more favorable than China Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
China Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Equillium	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Equillium beats China Pharma on 9 of the 14 factors compared between the two stocks.